Morten Olesen

Medicine & Life Sciences

1. mirabegron 100%
2. Atrial Fibrillation 80%
3. Overactive Urinary Bladder 75%
4. Muscarinic Antagonists 73%
5. Prescriptions 52%
6. Denmark 52%
7. Dicloxacillin 50%
8. Lip Neoplasms 47%
9. Floxacillin 47%
10. Meta-Analysis 44%
11. Confidence Intervals 40%
12. Randomized Controlled Trials 40%
13. Hydrochlorothiazide 38%
14. Heart Valves 33%
15. Gadolinium 32%
16. Myocardial Infarction 31%
17. Warfarin 31%
18. Systematic Reviews 30%
19. Embolism 30%
20. Stroke 30%
21. Angiotensin-Converting Enzyme Inhibitors 29%
22. Hydroxymethylglutaryl-CoA Reductase Inhibitors 29%
23. Anticoagulants 27%
24. Cohort Studies 27%
25. Case-Control Studies 26%
26. Mortality 26%
27. Therapeutics 25%
28. Placebos 25%
29. Mineralocorticoid Receptor Antagonists 24%
30. General Practitioners 22%
31. Heart Failure 21%
32. Databases 21%
33. Angiotensin Receptor Antagonists 20%
34. Pharmacology 19%
35. Hemorrhage 19%
36. Pharmaceutical Preparations 18%
37. Ivabradine 18%
38. Penicillin V 18%
39. Population 17%
40. Information Storage and Retrieval 15%
41. Propensity Score 15%
42. Dabigatran 14%
43. Squamous Cell Carcinoma 13%
44. Registries 13%
45. Incidence 11%
46. Odds Ratio 11%
47. Neoplasms 10%
48. apixaban 10%
49. Survival 9%
50. Physicians 9%